IRBESARTAN

SynDRA canonical compound SYN0008355 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	AGTR1
Mechanism of action	Angiotensin receptor antagonist
Indication	diabetic nephropathy \| hypertension
Disease area	cardiology \| nephrology

All known targets

aprovel
irbesartan hydrochloride
karvea
ifirmasta
irbesartan HCl
Irbesartan bms
Irbesartan teva
Irbesartan zentiva
Sarbevel
BMS-186295
NSC-758696
SR-47436
Aprovel
Avapro
Ifirmasta
Irbesartan component of avalide
Irbesartan component of coaprovel
Irbesartan component of ibersartan/hydrochlorothiazide ibersartan
Irbesartan component of ibersartan/hydrochlorothiazide teva ibersartan
Irbesartan component of ibersartan/hydrochlorothiazide zentiva ibersartan
Irbesartan component of ifirmacombi
Irbesartan zentiva (previously irbesartan winthrop)
Karvea
Sabervel
SR 47436
BMS 186295
Irbesartan [USAN:INN]
UNII-J0E2756Z7N
CHEMBL1513
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[44]non-8-en-6-one
CHEBI:5959
C25H28N6O
YOSHYTLCDANDAN-UHFFFAOYSA-N
J0E2756Z7N
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[44]non-1-en-4-one
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[44]non-1-en-4-one
NCGC00095122-01
AK-57149